GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price traded up 2.8% during mid-day trading on Wednesday . The company traded as high as $8.33 and last traded at $8.33. 3,888 shares traded hands during trading, a decline of 95% from the average session volume of 79,718 shares. The stock had previously closed at $8.10.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on GHRS shares. JMP Securities reiterated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Thursday, September 5th.
Read Our Latest Analysis on GHRS
GH Research Trading Up 2.8 %
The stock has a market cap of $433.39 million, a PE ratio of -12.43 and a beta of 0.79. The business has a 50 day moving average of $8.15 and a 200-day moving average of $10.57.
GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. Research analysts expect that GH Research PLC will post -0.89 EPS for the current fiscal year.
Institutional Investors Weigh In On GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. raised its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 11.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,251,714 shares of the company's stock after acquiring an additional 664,381 shares during the quarter. RA Capital Management L.P. owned about 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
